Only TET2 mutations seemed to be enriched in our study in comparison with 46%‐60% in the literature, whereas ASXL1 is underrepresented in comparison with 26%‐40% literature values.13, 14 The presence of a TET2 mutations is inversely correlated with the presence of blast increase in the bone marrow in the CMML cohort (P = 0.0218). The gene discussed is ASXL1; the disease is chronic myelomonocytic leukemia.